DIRS.INFO The most relevant business & tech news

☆ 5 new weight-loss drugs to watch in the fight for the next Ozempic
▼ + stars: | 2024-11-16 | by ( ) www.businessinsider.com time to read: +8 min

"Forthcoming medications take the blockbuster GLP-1 medications and up the ante." Like semaglutide (the active ingredient in Ozempic and Wegovy), it works on GLP-1, a hormone that regulates blood sugar and appetite. CagriSema adds it to the already-popular drug semaglutide, which itself helps manage hunger and blood sugar levels. "Longer-acting versions of GLP-1 medications offer the potential for greater convenience and potentially improved adherence and sustained use over time," McGowan said. Timeline: Data from Phase II trials is expected later this year, and planning is underway for Phase III trials.

Persons: Eli Lilly, Dr, Christopher McGowan, Eli Lilly's, Ozempic, retatrutide, VK2735, we've, they're, McGowan Organizations: Pharma, Novo Nordisk, Viking Therapeutics, Triple, Therapeutics, FDA, orforglipron, Nordisk, Reuters Locations: GLP, Mounjaro, California

Stocks tumbled on Friday as the post-election rally fizzled and investors fretted over the path of interest rates. The S&P 500 slipped 1.32% and closed at 5,870.62, while the Nasdaq Composite fell 2.24% to 18,680.12. Declines in pharmaceutical stocks weighed on the 30-stock Dow and broader S&P 500, with Amgen down about 4.2% and Moderna off by 7.3%. The information technology sector of the S&P 500 was the worst performing corner of the market, down more than 2% as Nvidia, MetaPlatforms, Alphabet and Microsoft tumbled. The S&P 500 posted a weekly loss of 2.1%, while the Nasdaq Composite slid about 3.2%.

Persons: Stocks, Donald Trump, Robert F, Kennedy Jr, Tesla, ”, Kristy Akullian, “, Jerome Powell, Susan Collins, Dow Jones Organizations: Dow Jones Industrial, Nasdaq, Dow, Moderna, Department of Health, Human Services, P Biotech, Nvidia, Microsoft, Trump Trade, ” Traders, Federal, Boston, Street Locations: Americas, BlackRock

☆ We're overhauling our Bullpen watchlist — 3 stocks are gone, the rest stick around
▼ + stars: | 2024-11-15 | by ( Paulina Likos | ) www.cnbc.com time to read: +4 min

As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. A view of the New York Stock Exchange (NYSE) on Wall Street November 13, 2024, in New York City.

Persons: Jim Cramer, Jim, Brian Chesky, Trump, Marvell, Jim chalked, Matt Murphy's, we're, hasn't, Amgen's, it's, Jim Cramer's, Angela Weiss Organizations: Pepsico, RTX, Marvell Technology, Nvidia, AMD, Broadcom, Novartis, JPMorgan Healthcare, Dow Inc, Jim Cramer's Charitable, CNBC, New York Stock Exchange, AFP, Getty Locations: RTX, Russia, Ukraine, Swiss, China, New York City

☆ Amgen stock falls as analysts mull over weight loss drug’s bone density data
▼ + stars: | 2024-11-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. Amgen did not immediately respond to a request for comment on the dataThe drug is a promising potential competitor in the weight loss drug market. "On one hand, patients could naturally lose bone mineral density during weight loss treatment," Brayer wrote. But Brayer said, "on the other hand, this could be a non-starter because there seems to be a dose-dependent increase" in bone mineral density loss. Amgen is also aware of the "hypothetical concern" of bone mineral density loss, Yee said, citing the firm's discussions with management.

Persons: Amgen, Eli Lilly, Cantor Fitzgerald, Olivia Brayer, Eli, Wegovy, Brayer, Jefferies, Michael Yee, Yee, Evan Seigerman, hasn't, Seigerman Organizations: Novo Nordisk, BMO

☆ This Trump trade is an underappreciated opportunity, says Janus Henderson
▼ + stars: | 2024-11-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Financial and energy stocks have jumped since last week's election, but there's another area of opportunity that investors could be missing out on, according to Janus Henderson. The market has rallied since President-elect Donald Trump' s victory, although it took a breather on Tuesday. However, financial stocks may have "gotten in a bit ahead of themselves," said Jeremiah Buckley, a portfolio manager at Janus Henderson. In addition, there is great research and development happening in health care right now, especially in health-care services, Buckley added. Among the funds Buckley oversees at Janus Henderson is the U.S. Dividend Income Fund .

Persons: Janus Henderson, Donald Trump, Jeremiah Buckley, Trump, Buckley, Eli Lilly, Amgen Organizations: Trump, P Health Care Services, UnitedHealth, Gilead Sciences

☆ 11 surprising things from this earnings season, including my favorite stock so far
▼ + stars: | 2024-11-03 | by ( Jim Cramer | ) www.cnbc.com time to read: +17 min

Horton makes the most sense as a Kamala Harris stock because of a promised $25,000 toward a first home. I don't know if either candidate can pull off huge tariffs (Trump) or a credit (Harris). Here are eleven surprising things about this earnings season that you can store up and pull out when the election is confirmed. The deficit will begin to hurt the stock market hard next year even if the economy continues to cool. Away from the hyperscalers, I like Marvell , where CEO Matt Murphy bought $1 million worth of stock in the open market.

Persons: beckons, Joe Biden, Biden, Donald Trump, D.R, Horton, Kamala Harris, Harris, let's, Let's, Trump, haven't, Myers, Abbvie, Eli Lilly, Anat Askenazi's, Abbott, neonatologists, Reckitt, Jim Hurst, Danaher, Jason Hollar, It's, Amgen, That's, Estee Lauder, Parker, Pat Gelsinger's, He's, Matt Murphy, Jim Cramer's, Jim Cramer, Jim, David Paul Morris Organizations: U.S, NBC News, White, Ford Motor, Trump, Costco, Volkswagen, Bankers, Banco Santander, Apple, Amazon, GE Vernova, U.S ., Treasury, Merck, NEC, FDA, CDC, NIH, GE Healthcare, Cardinal Health, NPC, Nvidia, Caterpillar, Linde, Devices, heaven's, Intel, Marvell, Micron, Arista, Jim Cramer's Charitable, CNBC, Bloomberg, Getty Locations: Europe, Germany, China, Portugal, Ireland, Italy, Greece, Spain, It's, Santander, —, Bristol, U.S, Taiwan, Eaton, Dover, Norwegian, Caribbean, San Francisco

☆ Nvidia to replace Intel in Dow Jones Industrial Average
▼ + stars: | 2024-11-02 | by ( Lloyd Lee | Katherine Tangalakis-Lippert | ) www.businessinsider.com time to read: +4 min

Nvidia is replacing Intel in the Dow Jones Industrial Average, S&P Dow Jones Indices said Friday. AdvertisementNvidia is joining the Dow Jones Industrial Average, the S&P Dow Jones Indices said on Friday, replacing its rival Intel, which held the position for 25 years. AdvertisementThe Sherwin-Williams Company (SHW) will also replace Dow Inc. (DOW) in the index. The Dow Jones Industrial Average, or DJIA, is made up of 30 blue-chip companies, from Amazon to Walt Disney Co., and is often used as a benchmark for the broader US economy. Now, with its entrance into the DJIA, it only underlines the mainstream acceptance of Nvidia as a market leader.

Persons: Dow, —, Sherwin, missteps, Pat Gelsinger, Jensen Huang, Jensen, Dan Ives, JPMorgan Chase, Johnson, Goldman Sachs Organizations: Nvidia, Intel, Dow Jones, Service, Williams Company, Dow Inc, DOW, Walt Disney Co, Amazon Web Services, Corporate Finance Institute, Microsoft, Walmart, JPMorgan, UnitedHealth, Procter, Gamble Company, Cola Company, Chevron Corporation, Merck, Co, Cisco Systems, McDonald's Corporation, Business Machines Corporation, IBM, American Express Company, Caterpillar, Verizon Communications, Walt Disney Company, Goldman, Honeywell International, Nike, Boeing Company, Intel Corporation, 3M Company, Travelers Companies, Dow Locations: Amazon, Silicon Valley, Susquehanna

☆ The Setup: Roblox, Amgen and Mastercard
▼ + stars: | 2024-10-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe Setup: Roblox, Amgen and MastercardThe Investment Committee give you The Setup on some earnings reports this week.

Organizations: Amgen, Investment

☆ Here are Monday's biggest analyst calls: Nvidia, Broadcom, Apple, Tesla, Flutter, Caterpillar, Alphabet & more
▼ + stars: | 2024-10-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are the biggest calls on Wall Street on Monday: TD Cowen reiterates Nvidia as buy TD said Nvidia remains a top pick at the firm. Goldman Sachs upgrades Ibotta to buy from neutral Goldman Sachs reiterates Alphabet as buy Goldman lowered its price target on the stock to $208 per share from $217 citing a slew of headwinds for Alphabet. Wells Fargo upgrades Flutter to overweight from equal weight Wells says investors should buy the dip in shares of the gambling company. Goldman Sachs downgrades AutoZone to sell from buy Goldman downgraded the auto parts retailer due to "muted growth." Goldman Sachs upgrades Ibotta to buy from neutral Goldman says it likes the growth opportunity for the mobile tech company.

Persons: TD Cowen, Mizuho, Goldman Sachs, Goldman, Wells, Truist, Morgan Stanley, Caterpillar, Piper Sandler, Tesla, Piper, wouldn't, it's, Baird, KeyCorp, Jefferies, it's bullish, Stock, GOOS, AppLovin, Oppenheimer Organizations: Nvidia, NVIDIA, Away Tech, Mizuho, AMD, Broadcom, UBS, Partners, Surgery Partners, Apple, VF Corp, Vans, UW, Walmart Locations: Wells Fargo, China

☆ Calls of the Day: Amgen, Albemarle, Tesla, Broadcom and Caterpillar
▼ + stars: | 2024-10-14 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Amgen, Albemarle, Tesla, Broadcom and CaterpillarThe Investment Committee discuss the latest Calls Of The Day.

Organizations: Broadcom, Caterpillar The Investment Locations: Albemarle, Tesla

☆ Jim Cramer is holding on to Starbucks as new CEO starts making changes
▼ + stars: | 2024-10-14 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "Don't sell the stock," Jim urged, outlining several reasons why investors should hold in his Sunday column . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, he'd, Brian Niccol, Niccol, we've, Stocks, Jim Cramer's Organizations: CNBC, Apple, Evercore ISI, Constellation Brands, Wall Street Journal, Boeing, VF Corp, Southwest Airlines Locations: Wells Fargo

☆ Final Trades: John Deere, Copart, Amgen and the IYH
▼ + stars: | 2024-10-09 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: John Deere, Copart, Amgen and the IYHThe Investment Committee give you their top stocks to watch for the second half.

Persons: John Deere Organizations: Investment

☆ Beyond Novo: Fund manager likes this under-the-radar pharma stock with a weight loss drug in the works
▼ + stars: | 2024-10-04 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

"Maybe that weight loss product (by United Laboratories) works, maybe it doesn't. United Laboratories' price-to-earnings of 5.8 times is a fraction of the 34.3 times that Novo Nordisk is trading at, Peche added. [United Laboratories] is making smooth progress in R & D and targets to launch Liraglutide in 2024. Their comments follow United Laboratories' "faster than expected earnings" growth in the first half of the year. Analysts' average price target on United Laboratories is 12.95 Hong Kong dollars, giving it 28.2% potential upside.

Persons: Sean Peche, it's, Peche, there's, that's, Eli Lilly, Amgen, Carol Dou, Sunny Chen, UOB Kay Hian, bode Organizations: Novo Nordisk, Ranmore Fund Management, United Laboratories, Pfizer, AstraZeneca, Global Equity Fund, Hong, Hong Kong bourse, HK Locations: Hong Kong, Novo, Europe, U.S

☆ TV personality La La Anthony on why you should have multiple streams of income: You're 'crazy if you only do one thing'
▼ + stars: | 2024-10-02 | by ( Renée Onque | ) www.cnbc.com time to read: +4 min

And TV personality La La Anthony says, "you'll be crazy if you only do one thing. You got to do multiple things and get multiple things going for yourself." "There was a time where you could only do one thing, or people only wanted you to do one thing," Anthony tells CNBC Make It. But I think now it's a different time, a different day, where everyone's doing multiple things." She suggests not allowing fear to creep in and cause you to think that you won't be able to balance multiple things you're passionate about.

Persons: La La Anthony, Anthony, isn't, we've, Get Organizations: MTV, Starz, CNBC, Amgen

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ Calls of the Day: Salesforce, Walmart, Pepsico and Amgen
▼ + stars: | 2024-09-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Salesforce, Walmart, Pepsico and AmgenThe Investment Committee debate the latest Calls Of The Day.

Organizations: Walmart, Pepsico

☆ Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more
▼ + stars: | 2024-09-27 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

That came after short-seller Hindenburg Research revealed last month it had taken a short position in the company, citing "fresh evidence of accounting manipulation." Cassava Sciences — The biotech company fell 11% after agreeing to pay $40 million to settle a case with the Securities and Exchange Commission. Wynn Resorts — The stock rose about 6% thanks to an upgrade to overweight from equal weight at Morgan Stanley. Amgen — The biotech's shares rose 2% after Cantor Fitzgerald initiated research coverage with an overweight rating. — The aerospace and defense stock added 16% following a price target increase from KeyBanc Capital Markets, which retained an overweight investment rating.

Persons: Bristol Myers, Hindenburg, Morgan Stanley, Amgen, Cantor Fitzgerald, Olivia Brayer, Michael Leshock, — CNBC's Sean Conlon, Alex Harring, Yun Li, Hakyung Kim, Samantha Subin, Pia Singh Organizations: Bristol Myers Squibb, Food and Drug Administration, Bristol, Nordisk —, JPMorgan, Wall, Costco Wholesale, Revenue, Wall Street Journal, Justice Department, Hindenburg Research, Securities and Exchange Commission, Wynn Resorts, UAE, HP Inc, Bank of America, KeyBanc Locations: Nordisk — U.S, Danish, Las Vegas

☆ Here are Friday's biggest analyst calls: Apple, Dell, Wynn, Walmart, Best Buy, Costco, Netflix & more
▼ + stars: | 2024-09-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Piper Sandler upgrades Accenture to overweight from equal weight Piper upgraded the IT company following its earnings report. Goldman Sachs reiterates Costco as buy Goldman says it's sticking with the stock following earnings on Thursday. Citi downgrades Dollar General to sell from neutral Citi says it sees too many competitive challenges. JPMorgan adds Best Buy to the focus list JPMorgan says it sees an "improving product cycle" for Best Buy. Bank of America downgrades HP to neutral from buy The firm says it sees slowing earnings per share growth.

Persons: Morgan Stanley, Wynn, Piper Sandler, Piper, Goldman Sachs, Goldman, it's bullish, it's, Raymond James, Mercado, Roth MKM, Roth, Cantor Fitzgerald Organizations: Wynn Resorts, Deutsche Bank reinstates Dell, Deutsche, DELL, NASDAQ, Costco, " Bank of America, Apple, Bank of America, Apple Intelligence, UBS, Vista Energy, Citi, Pepsi Citi, Catalyst, Walmart, Cava, Mercado Libre, JPMorgan, Chesapeake Energy, Barclays, Netflix, HP Locations: UAE, Macau, BMBL, CAVA, HPQ

☆ Microsoft just punted on a big AI decision. It could be a bad sign.
▼ + stars: | 2024-09-26 | by ( Ashley Stewart | ) www.businessinsider.com time to read: +5 min

Read previewMicrosoft has pressed pause on a major AI overhaul of its popular 365 software suite, according to people familiar with the matter. CEO Satya Nadella and his senior leadership team held executive reviews this summer to consider options that included repackaging new AI features into existing licenses or creating a more expensive bundle with AI capabilities. Other changes Microsoft is considering for its 365 software bundles is a new suite just for security features, the people also said. In recent months, some customers and investors have begun to question the value of generative AI technology, including Microsoft's Copilot AI assistant tool. That's in addition to the monthly cost of Microsoft's 365 software bundles.

Persons: —, Satya Nadella, OpenAI's, It's, Judson Althoff Organizations: Service, Business, Microsoft, Chief, Vodafone, Amgen, Microsoft's Productivity, Processes

☆ Here are 3 stocks to buy after the Fed's 'crisis level cut,' according to one strategist
▼ + stars: | 2024-09-23 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +4 min

The move they made is a big cut," SlateStone Wealth's Kenny Polcari told CNBC's " Street Signs Asia " on Sept. 19. Calling it a "crisis level cut," he added that "people [are] scratching their heads, going, what's it really mean?" Federal Reserve Chair Jerome Powell stressed that the big rate cut does not signal that the risk of a recession is elevated. According to FactSet data, of the 20 analysts covering the stock, 18 give it a buy or overweight rating, while two have a hold rating. Biotech play Another stock Polcari is bullish on is biopharmaceutical player Amgen , given its pipeline of new products .

Persons: Kenny Polcari, CNBC's, Jerome Powell, Polcari, Amgen, — CNBC's Sean Conlon Organizations: U.S, Biotech, U.S . Food, Drug Administration, Euronext, Nasdaq, Nvidia Locations: Federal, U.S, Amgen, Euronext Amsterdam, Dutch, ASML

☆ Biotech stocks are an unappreciated way to profit from lower rates, Goldman says
▼ + stars: | 2024-09-18 | by ( Scott Schnipper | ) www.cnbc.com time to read: +3 min

Biotechnology stocks offer an under-the-radar and unappreciated way to profit from the central bank's looming campaign to start cutting the cost of borrowing, according to Goldman Sachs. Investors may have already begun to anticipate the effect of lower rates on some biotech companies. IBB .SPX mountain 2024-06-30 The iShares Biotechnology ETF has risen more than twice as much as the S & P 500 this quarter. The iShares Biotech ETF is up 7.7% this quarter while the Nasdaq Biotech Index has advanced 7.4%, more than double the 3.2% gain in the S & P 500 since June 30. Year-to-date, Regeneron is up 30.6% and Vertex by 18.3%, both outperforming the 18.1% rise in the S & P 500.

Persons: Goldman Sachs, John Flood, Goldman, Flood, Regeneron Organizations: Biotechnology, Federal Reserve, Gilead Sciences, Nasdaq Biotechnology, IQVIA Holdings, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals, iShares Biotech, Nasdaq Biotech Locations: Gilead

☆ These low-volatility stocks have a winning record and are attractively valued
▼ + stars: | 2024-08-11 | by ( Pia Singh | In | ) www.cnbc.com time to read: +4 min

These stocks have low share price volatility over the past five years, and their total return — including share price gains and dividends — are greater than the S & P 500's over the past five years. Take a look at the names below: Health-care companies Amgen , UnitedHealth Group and AbbVie are among the names with low volatility and strong returns in recent years. Pharmaceutical company AbbVie's roughly 262% gain over the past five years is the highest of the stocks in the group. Amgen's share price has a 5-year total return of 104%, making it a steady grower, but still the slowest of the list. Other stocks with low volatility and attractive valuations include automotive replacement parts retailer AutoZone and insurance company Aflac .

Persons: Stocks, They're, Morgan Stanley, Wells, Mohit Bansal, TD Cowen, Kannan Venkateshwar, — CNBC's Christopher Hayes Organizations: CNBC, UnitedHealth, Pharmaceutical, Morgan Stanley Wealth Management, Humira, Barclays, Mobile

☆ Eli Lilly reports earnings Thursday. Here's what Wall Street is watching
▼ + stars: | 2024-08-07 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. While Eli Lilly's stock remains up about 32% year to date, concerns about increasing competition in the category have resulted in a nearly 16% decline for Lilly shares over the past month. Eli Lilly is making similar attempts with Zepbound, but its launch is at an earlier stage than Wegovy. Second-quarter sales of Ozempic, Novo's diabetes treatment, rose 4% from the first quarter, while Wegovy revenue grew 24% quarter over quarter. Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness.

Persons: Eli Lilly, Eli, Lilly, Wells, Mohit Bansal, Ozempic, Bansal, Emily Field, David Song, Song, Chris Schott, Schott Organizations: Novo Nordisk, LSEG, Lilly's, Management, Food and Drug Administration, Barclays, Tema, JPMorgan Locations: Wells Fargo, IQVIA, Amgen, MariTide, Novo, CagriSema

☆ Tuesday's big stock stories: What's likely to move the market in the next trading session
▼ + stars: | 2024-08-05 | by ( Jason Gewirtz | ) www.cnbc.com time to read: +2 min

It's now 18% from the February 52-week high. The stock is 17% from the April 52-week high. Dow Winners There are only four Dow stocks that are up in the last three days. Shares are 1.7% from the July 24 52-week high. The stock is 11% from the January 52-week high.

Persons: Russell, Crypto, Michael Saylor, MicroStrategy, Cleanspark, Joe Hinrichs, It's, Johnson, McDonald's Organizations: CNBC, Nasdaq, Dow Jones, Galaxy, CSX, Caterpillar, Dow, Procter, Gamble, Johnson

☆ Here are 4 things we're watching closely in the stock market this week
▼ + stars: | 2024-08-04 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Stocks had a rough week, topped off with a pummeling Friday after the July jobs data came in weaker than expected. Until then, bad economic news was good news for the stock market, because it meant the Federal Reserve would start cutting interest rates sooner. On Thursday, a drop in U.S. manufacturing activity for July and a jump in initial jobless claims dragged down the market. Next week is light on economic data, so expect earnings reports and CEO commentaries to drive the market action. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Stocks, Dow Jones, Jim Cramer, would've, Eli Lilly, Mounjaro, Berkshire Hathaway, Krystal, Tyson, BAX, Owens, Walt, Oscar Health, CRON, Krispy, Papa, Jim Cramer's, Jim Organizations: Nasdaq, Dow, Reserve, Broadcom, Devices, Palo Alto, PMI, Wynn Resorts, Investors, Wynn, Wynn Palace, U.S . Disney, Management, and Drug Administration, Carlyle Group, Krystal Biotech, Tyson Foods, TSN, Alpha Metallurgical Resources, BioCryst Pharmaceuticals, Axsome Therapeutics, Technologies, Clover Health, Realty Income Corp, Avis Budget Group, CSX Corp, CSX, Simon Property Group, Sterling Construction Company, Teradata Corp, Yum China Holdings, ZoomInfo Technologies, Holdings, Caterpillar, Baxter International, Vulcan Materials Company, Allegheny Technologies Incorporated, Constellation Energy Group, Marathon Petroleum Corp, Owens Corning Inc, Duke Energy Corp, GXO Logistics, Brands, Builders, Wynn Resorts Ltd, WYNN, Rivian Automotive, Devon Energy Corp, GigaCloud Technology Inc, Lumen Technologies, VF Corp, Walt Disney Co, Novo Nordisk, CVS Health, Aurora Cannabis Inc, Emerson Electric Co, Sony Group Corporation, SONY, Inc, ODP Corporation, Icahn Enterprises, MannKind Corp, ACM Research, Brink's Company, AppLovin Corporation, Digital Turbine, Sarepta Therapeutics, Occidental Petroleum Corp, Bros, SolarEdge Technologies, Aspen, Coeur D'Alene Mines Corp, Co, Vistra Energy, Cheniere Energy, Cronos, Himax Technologies, Properties Trust, Papa John's, Paramount Global, Trade, Lab, B2Gold Corp, Honest Company, Gilead Sciences, Growth, Nikola Corporation, Embraer, New Fortress Energy, Construction, Jim Cramer's Charitable, CNBC, Disney, Pixar Locations: Palo, Macau, Las Vegas, Boston, Vegas, Wynn Macau, China, Novo, Coeur, Gilead

Search resuls for: "Amgen"

25 mentions found